Advances in cancer immunotherapy 2019 - latest trends.

Clinical Trials as Topic Combined Modality Therapy Humans Immunotherapy / methods Immunotherapy, Adoptive Neoplasms / immunology Protein Kinases / pharmacology
Chimeric antigen receptor T cells (CAR T cells) Immunotherapy Programmed cell death protein 1 (PD-1) Programmed cell death protein ligand 1 (PD-L1) Regional distribution Trends

Journal

Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647

Informations de publication

Date de publication:
19 Jun 2019
Historique:
received: 31 05 2019
accepted: 03 06 2019
entrez: 21 6 2019
pubmed: 21 6 2019
medline: 4 12 2019
Statut: epublish

Résumé

Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies. The two main drivers behind this success are checkpoint inhibitors (CPIs) and chimeric antigen receptor (CAR) T cells. This review summarizes seminal findings from clinical and translational studies recently presented or published at important meetings or in top-tier journals, respectively. For checkpoint blockade, current studies focus on combinational approaches, perioperative use, new tumor entities, response prediction, toxicity management and use in special patient populations. Regarding cellular immunotherapy, recent studies confirmed safety and efficacy of CAR T cells in larger cohorts of patients with acute lymphoblastic leukemia or diffuse large B cell lymphoma. Different strategies to translate the striking success of CAR T cells in B cell malignancies to other hematological and solid cancer types are currently under clinical investigation. Regarding the regional distribution of registered clinical immunotherapy trials a shift from PD-1 / PD-L1 trials (mainly performed in the US and Europe) to CAR T cell trials (majority of trials performed in the US and China) can be noted.

Identifiants

DOI: 10.1186/s13046-019-1266-0 PMID: 31217020 PMC: PMC6585101
pubmed: 31217020
doi: 10.1186/s13046-019-1266-0
pii: 10.1186/s13046-019-1266-0
pmc: PMC6585101
doi:

Substances chimiques

Protein Kinases EC 2.7.-

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

268

Subventions

Organisme : Else Kröner-Fresenius-Stiftung (DE)
ID : Else Kröner-Forschungskolleg: Cancer Immunotherapy

Références

Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Nat Med. 2019 May;25(5):767-775
pubmed: 31011208
Sci Transl Med. 2015 Aug 26;7(302):302ra133
pubmed: 26311728
Int J Cancer. 2019 May 1;144(9):2303-2312
pubmed: 30446996
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Immunol Rev. 2014 Jan;257(1):83-90
pubmed: 24329791
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Transfus Med Hemother. 2019 Feb;46(1):4-13
pubmed: 31244577
Oncotarget. 2017 Jun 6;8(23):38056-38060
pubmed: 28445137
Nat Med. 2019 May;25(5):814-824
pubmed: 30962585
Science. 2011 Mar 25;331(6024):1612-6
pubmed: 21436454
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Cell. 2018 May 31;173(6):1439-1453.e19
pubmed: 29856956
Br J Cancer. 2006 May 22;94(10):1478-84
pubmed: 16641897
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
Ann Oncol. 2017 May 01;28(5):1130-1136
pubmed: 28327969
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
Sci Rep. 2016 Jan 13;6:18851
pubmed: 26758806
Nat Biotechnol. 2018 Oct;36(9):847-856
pubmed: 30102295
J Immunother Cancer. 2018 Jan 23;6(1):8
pubmed: 29357948
Eur J Cancer. 2018 Mar;91:21-29
pubmed: 29331748
Blood. 2018 Jan 18;131(3):311-322
pubmed: 29122757
J Clin Oncol. 2021 Jan 1;39(1):30-37
pubmed: 32822275
Front Immunol. 2018 Sep 25;9:2166
pubmed: 30319627
Nature. 2015 May 7;521(7550):94-8
pubmed: 25924065
JAMA Oncol. 2018 Mar 01;4(3):374-378
pubmed: 28975219
Clin Cancer Res. 2014 Jun 1;20(11):2831-7
pubmed: 24879823
Oncoimmunology. 2017 Mar 31;6(5):e1310358
pubmed: 28638732
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
Clin Cancer Res. 2018 Oct 15;24(20):4960-4967
pubmed: 29685882
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
J Gastrointest Oncol. 2018 Aug;9(4):610-617
pubmed: 30151257
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Cell Rep. 2017 Dec 12;21(11):3205-3219
pubmed: 29241547
Cancer Immunol Res. 2019 Apr;7(4):528-533
pubmed: 30936089
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Clin Cancer Res. 2018 Apr 15;24(8):1872-1880
pubmed: 29330207
EMBO Mol Med. 2017 Sep;9(9):1183-1197
pubmed: 28765140
Nat Med. 2019 Jun;25(6):947-953
pubmed: 31011207
Cancer Discov. 2015 Dec;5(12):1232
pubmed: 26516064
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
Oncogene. 2010 Jan 28;29(4):482-91
pubmed: 19881547
Immunology. 2018 Nov;155(3):283-284
pubmed: 30320408
Nat Med. 2018 Jun;24(6):724-730
pubmed: 29867227
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Clin Cancer Res. 2011 Apr 1;17(7):1915-23
pubmed: 21355078
Ann Surg Oncol. 2010 Jul;17(7):1747-57
pubmed: 20119674
Ann Surg Oncol. 2008 May;15(5):1454-63
pubmed: 18299934
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Cancer Immunol Res. 2017 Sep;5(9):755-766
pubmed: 28848055
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70
pubmed: 14967443
Ann Oncol. 2018 Dec 1;29(12):2348-2355
pubmed: 30346475
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Cancer Res. 2010 Apr 15;70(8):3052-61
pubmed: 20388795
Br J Cancer. 2019 Jan;120(1):26-37
pubmed: 30413825
J Immunother Cancer. 2019 Apr 3;7(1):99
pubmed: 30944023
Front Pharmacol. 2014 Oct 28;5:235
pubmed: 25389405
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Br J Cancer. 2010 Jan 5;102(1):115-23
pubmed: 19997099
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Cancer Cell. 2019 Feb 11;35(2):221-237.e8
pubmed: 30753824
Oncotarget. 2016 Apr 5;7(14):18508-20
pubmed: 26918344
J Immunother Cancer. 2018 Aug 31;6(1):83
pubmed: 30170622
Oncoimmunology. 2018 Apr 20;7(8):e1452581
pubmed: 30221046
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
Nat Med. 2018 Nov;24(11):1655-1661
pubmed: 30297911
Ann Oncol. 2018 Jan 1;29(1):84-91
pubmed: 29228097
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
JCI Insight. 2019 Apr 2;5:
pubmed: 30938714
Immunol Rev. 2017 Nov;280(1):249-279
pubmed: 29027221
Cancer Immunol Res. 2015 Jun;3(6):610-9
pubmed: 25701325
Br Med J. 1908 Oct 17;2(2494):1146-8
pubmed: 20764084

Auteurs

Stephan Kruger (S)

Department of Medicine III, University Hospital Munich, LMU Munich, Marchioninistr. 15, D-81377, Munich, Germany. stephan.kruger@med.uni-muenchen.de.
Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany. stephan.kruger@med.uni-muenchen.de.

Matthias Ilmer (M)

Department of General, Visceral, and Transplantation Surgery, University Hospital, LMU Munich, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Sebastian Kobold (S)

Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany.

Bruno L Cadilha (BL)

Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany.

Stefan Endres (S)

Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany.

Steffen Ormanns (S)

Institute of Pathology, LMU Munich, Munich, Germany.

Gesa Schuebbe (G)

Department of Medicine III, University Hospital Munich, LMU Munich, Marchioninistr. 15, D-81377, Munich, Germany.

Bernhard W Renz (BW)

Department of General, Visceral, and Transplantation Surgery, University Hospital, LMU Munich, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Jan G D'Haese (JG)

Department of General, Visceral, and Transplantation Surgery, University Hospital, LMU Munich, Munich, Germany.

Hans Schloesser (H)

University Hospital of Cologne, Cologne, Germany.

Volker Heinemann (V)

Department of Medicine III, University Hospital Munich, LMU Munich, Marchioninistr. 15, D-81377, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Marion Subklewe (M)

Department of Medicine III, University Hospital Munich, LMU Munich, Marchioninistr. 15, D-81377, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Gene Center LMU, Munich, Germany.

Stefan Boeck (S)

Department of Medicine III, University Hospital Munich, LMU Munich, Marchioninistr. 15, D-81377, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Jens Werner (J)

Department of General, Visceral, and Transplantation Surgery, University Hospital, LMU Munich, Munich, Germany.

Michael von Bergwelt-Baildon (M)

Department of Medicine III, University Hospital Munich, LMU Munich, Marchioninistr. 15, D-81377, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Center for Molecular Medicine Cologne (CMMC), Cologne, Germany.
Gene Center LMU, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Advances in cancer immunotherapy 2019 - latest trends.
questionsmedicales.fr › Thérapeutique › Association thérapeutique › Advances in cancer immunotherapy 2019 - latest trends.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Advances in cancer immunotherapy 2019 - latest trends.
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Advances in cancer immunotherapy 2019 - latest trends.
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Immunothérapie adoptive › Advances in cancer immunotherapy 2019 - latest trends.
questionsmedicales.fr › Tumeurs › Advances in cancer immunotherapy 2019 - latest trends.
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Phosphotransferases › Phosphotransferases (Alcohol Group Acceptor) › Protein kinases › Advances in cancer immunotherapy 2019 - latest trends.